These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 21437893)
1. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Chang JY; Komaki R; Lu C; Wen HY; Allen PK; Tsao A; Gillin M; Mohan R; Cox JD Cancer; 2011 Oct; 117(20):4707-13. PubMed ID: 21437893 [TBL] [Abstract][Full Text] [Related]
2. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865 [TBL] [Abstract][Full Text] [Related]
3. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Chang JY; Komaki R; Wen HY; De Gracia B; Bluett JB; McAleer MF; Swisher SG; Gillin M; Mohan R; Cox JD Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1350-7. PubMed ID: 21251767 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799 [TBL] [Abstract][Full Text] [Related]
5. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842 [TBL] [Abstract][Full Text] [Related]
7. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Koay EJ; Lege D; Mohan R; Komaki R; Cox JD; Chang JY Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1093-100. PubMed ID: 22543217 [TBL] [Abstract][Full Text] [Related]
8. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Socinski MA; Rosenman JG; Halle J; Schell MJ; Lin Y; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC Cancer; 2001 Sep; 92(5):1213-23. PubMed ID: 11571735 [TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067 [TBL] [Abstract][Full Text] [Related]
10. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394 [TBL] [Abstract][Full Text] [Related]
11. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942 [TBL] [Abstract][Full Text] [Related]
12. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375 [TBL] [Abstract][Full Text] [Related]
13. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer]. Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Chang JY; Zhang W; Komaki R; Choi NC; Chan S; Gomez D; O'Reilly M; Jeter M; Gillin M; Zhu X; Zhang X; Mohan R; Swisher S; Hahn S; Cox JD Radiother Oncol; 2017 Feb; 122(2):274-280. PubMed ID: 28139305 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135 [TBL] [Abstract][Full Text] [Related]
16. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062 [TBL] [Abstract][Full Text] [Related]
18. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
19. High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study. Oshiro Y; Okumura T; Kurishima K; Homma S; Mizumoto M; Ishikawa H; Onizuka M; Sakai M; Goto Y; Hizawa N; Sato Y; Sakurai H J Radiat Res; 2014 Sep; 55(5):959-65. PubMed ID: 24864278 [TBL] [Abstract][Full Text] [Related]
20. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]